Predictive Modeling Using a Somatic Mutational Profile in Ovarian High Grade Serous Carcinoma

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Sohn, Insuk ^a   Sung, Chang Ohk ^b  

^a Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; COMPUTER ANALYSIS; EXOME; FEMALE; GENETIC ANALYSIS; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; LOW RISK POPULATION; MAJOR CLINICAL STUDY; OVARIAN HIGH GRADE SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; VALIDATION PROCESS;

AGED; AREA UNDER CURVE; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84872225199     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054089     Document Type: Article

References (25)

1. Simon R, Radmacher MD, Dobbin K, McShane LM, (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18.
2. Simon RM, Subramanian J, Li MC, Menezes S, (2011) Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Brief Bioinform 12: 203-214.
3. Waldron L, Pintilie M, Tsao MS, Shepherd FA, Huttenhower C, et al. (2011) Optimized application of penalized regression methods to diverse genomic data. Bioinformatics 27: 3399-3406.
4. Molinaro AM, Simon R, Pfeiffer RM, (2005) Prediction error estimation: a comparison of resampling methods. Bioinformatics 21: 3301-3307.
5. Moynahan ME, Pierce AJ, Jasin M, (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7: 263-272.
6. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, et al. (1998) Involvement of Brca2 in DNA repair. Mol Cell 1: 347-357.
7. Xia F, Taghian DG, DeFrank JS, Zeng ZC, Willers H, et al. (2001) Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A 98: 8644-8649.
8. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, et al. (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306: 1557-1565.
9. Foulkes WD, (2006) BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 5: 135-142.
10. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, et al. (2011) Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29: 3008-3015.
11. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, et al. (1999) BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 59: 3547-3551.
12. The Cancer Genome Atlas Research Network, (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
13. Sohn I, Jung WY, Sung CO, (2012) Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer. Gynecol Oncol 126: 103-108.
14. Heagerty PJ, Zheng Y, (2005) Survival model predictive accuracy and ROC curves. Biometrics 61: 92-105.
15. Heagerty PJ, Lumley T, Pepe MS, (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344.
16. Azuaje F, (2003) Genomic data sampling and its effect on classification performance assessment. BMC Bioinformatics 4: 5.
17. Braga-Neto UM, Dougherty ER, (2004) Is cross-validation valid for small-sample microarray classification? Bioinformatics 20: 374-380.
18. Hickey JM, Veerkamp RF, Calus MP, Mulder HA, Thompson R, (2009) Estimation of prediction error variances via Monte Carlo sampling methods using different formulations of the prediction error variance. Genet Sel Evol 41: 23.
19. Gallagher DJ, Konner JA, Bell-McGuinn KM, Bhatia J, Sabbatini P, et al. (2011) Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol 22: 1127-1132.
20. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, et al. (2011) Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121: 358-363.
21. McConville CM, Stankovic T, Byrd PJ, McGuire GM, Yao QY, et al. (1996) Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet 59: 320-330.
22. Bowtell DD, (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808.
23. Sabatier R, Finetti P, Cervera N, Birnbaum D, Bertucci F, (2009) Gene expression profiling and prediction of clinical outcome in ovarian cancer. Crit Rev Oncol Hematol 72: 98-109.
24. Bookman MA, (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21: 149s-167s.
25. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, et al. (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 27: 2686-2691.